Semaphorin-6D (SEMA6D)

Semaphorin-6D is a type I transmembrane glycoprotein belonging to the semaphorin family, best known for roles in axon guidance, organogenesis, and cell signaling[2][3]. It consists of a sema domain, a PSI domain, a transmembrane segment, and an extended cytoplasmic portion, and engages in both forward (as a ligand) and reverse (as a receptor) signaling through interactions with Plexin-A1 and Plexin-A4[5][2][3]. SEMA6D is expressed in neuronal, cardiac, immune, and mesenchymal tissues, regulating neural patterning, cardiac morphogenesis, and immune responses. Its biological roles also include influencing epithelial-mesenchymal transition and tumor behavior, as SEMA6D expression modulates cell proliferation, migration, and cancer cell invasiveness. Genetic studies link SEMA6D to autism spectrum disorder and inflammatory bowel disease, and in cardiac and tumor contexts, its signaling fine-tunes cell migration, proliferation, and tissue patterning via interaction with key receptor kinases and adaptor proteins[1][2][3][4][6]. No approved drugs currently target SEMA6D directly, and clinical use as a biomarker or drug target is investigational.

Other names

Semaphorin-6DSEMA6DKIAA1479FLJ11598sema domain transmembrane domain and cytoplasmic domain (semaphorin) 6D

Null (no currently approved drugs known to directly target SEMA6D; function involves interaction with Plexin-A1 and Plexin-A4 as receptors leading to downstream signaling via pathways such as Rho GTPases, Abl kinase, Notch, and others)[2][3][1].